Aevi Genomic Medicine (GNMX) Issues Earnings Results, Beats Expectations By $0.03 EPS

Aevi Genomic Medicine (NASDAQ:GNMX) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03, MarketWatch Earnings reports.

NASDAQ GNMX traded down $0.10 on Friday, reaching $1.20. The company had a trading volume of 59,662 shares, compared to its average volume of 159,275. The company has a market capitalization of $64.09 million, a PE ratio of -1.45 and a beta of 0.61. Aevi Genomic Medicine has a 52 week low of $0.83 and a 52 week high of $2.65.

In related news, Director Sol J. Barer acquired 2,551,020 shares of the company’s stock in a transaction that occurred on Wednesday, August 15th. The stock was acquired at an average price of $0.96 per share, for a total transaction of $2,448,979.20. Following the completion of the acquisition, the director now owns 1,028,032 shares of the company’s stock, valued at approximately $986,910.72. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 11.70% of the company’s stock.

About Aevi Genomic Medicine

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.

See Also: Fundamental Analysis – How It Helps Investors

Earnings History for Aevi Genomic Medicine (NASDAQ:GNMX)

Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with's FREE daily email newsletter.

Leave a Reply